Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EBT (2022 - 2025)

Oramed Pharmaceuticals' EBT history spans 4 years, with the latest figure at $81.5 million for Q4 2025.

  • For Q4 2025, EBT changed N/A year-over-year to $81.5 million; the TTM value through Dec 2025 reached $147.0 million, changed N/A, while the annual FY2025 figure was $75.3 million, 573.14% up from the prior year.
  • EBT reached $81.5 million in Q4 2025 per ORMP's latest filing, up from $59.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $81.5 million in Q4 2025 to a low of -$18.5 million in Q3 2024.
  • Average EBT over 4 years is $6.8 million, with a median of -$3.3 million recorded in 2023.
  • Peak YoY movement for EBT: surged 925.44% in 2024, then tumbled 560.1% in 2025.
  • A 4-year view of EBT shows it stood at -$12.3 million in 2022, then skyrocketed by 208.49% to $13.3 million in 2023, then crashed by 239.21% to -$18.5 million in 2024, then soared by 540.12% to $81.5 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EBT are $81.5 million (Q4 2025), $59.5 million (Q3 2025), and $13.1 million (Q2 2025).